As the population of those aged 65 and over continues to grow, so does the diversity of the U.S. population. In fact, by 2060 approximately 27.7% of the population will be Hispanic, 15% will be African American, and 44% will be non-Hispanic white. Dr. Sid O’Bryant is the principal investigator of the Health & Aging Brain Study – Health Disparities (HABS-HD), which is the most comprehensive study of Alzheimer’s disease among the three largest racial/ethnic groups in the U.S. ever conducted – African Americans, Hispanics, non-Hispanic whites.

The goal of the HABS-HD program is to understand the life course factors, including biological, sociocultural, environmental, and behavioral, that impact risk for Alzheimer’s disease in late life. This work will ultimately lead to population-specific precision medicine approaches to treating and preventing Alzheimer’s disease (i.e., “treating your Alzheimer’s disease”). In addition to being a global leader in health disparities in cognitive aging, Dr. O’Bryant is a global expert in the use of blood-based biomarkers for the generation of a precision medicine approach to novel diagnostic and therapeutic strategies for Alzheimer’s disease, Parkinson’s disease, Dementia with Lewy Bodies and Alzheimer’s disease among adults with Down Syndrome.